Spruce Biosciences Says On March 16, Entered Termination Agreement With Kaken Pharmaceutical; Collaboration Agreement With Kaken Pharmaceutical To Terminate Effective March 31, 2026; All Licenses & Rights Granted By Co To Kaken To Be Terminated; No Unearned Milestone Payments Or Royalties

Spruce Biosciences announced that it has entered into a termination agreement with Kaken Pharmaceutical, effective March 31, 2026, which will end their collaboration agreement. As a result, all licenses and rights granted by Spruce to Kaken will be terminated. The company stated that there will be no unearned milestone payments or royalties associated with this termination.